Windward Bio AG is a Switzerland-based company primarily engaged in the biotechnology and biopharmaceutical industry. The Company focuses on the development of ultra-long-acting antibody medicines for immunological, respiratory, and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. Their key product is WIN378, which is a monoclonal antibody therapeutic that targets thymic stromal lymphopoietin (TSLP). It aims to reduce inflammation associated with respiratory diseases and provide longer dosing intervals for patients. The Company is also developing WIN027, a bispecific antibody targeting TSLP and interleukin-13 (IL-13) for immunological disorders.